Back to Search
Start Over
Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.
- Source :
-
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Dec; Vol. 9 (12). - Publication Year :
- 2021
-
Abstract
- Competing Interests: Competing interests: VO-M: Consultant or advisory role (Kite Gilead, Celgene, Novartis), travel grants (Kite Gilead, Celgene, Novartis, Roche, Takeda, Janssen), honoraria (Kite Gilead). SR: Consultant or advisory role (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), travel grants (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), honoraria (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead). AA-S: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). EG: Consultant or advisory role (Kite Gilead, Janssen, Genmab), research funding (Kite Gilead, Janssen, Roche). MD-B: Consultant or advisory role (Celgene, Novartis, Jazz, Astellas). AC: Consultant or advisory role (Novartis, Celgene), travel grants (Novartis, Celgene), honoraria (Novartis, Celgene). AF: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). LGR-L: Travel grants (Kite Gilead, Amgen, Janssen). ML: Honoraria (Grifols, Fresenius Kabi), research funding (Terumo BCT, Maco-Pharma). AM-R: Consultant or advisory role (Bristol Myers Squibb, Abbvie), travel grants (Kite Gilead, Roche, Takeda, Janssen, Abbvie), honoraria (Abbvie). EG-R: Honoraria (Novartis). PC: Consultant or advisory role (Kite Gilead, Celgene, Janssen), travel grants (Kite Gilead, MSD, Janssen). MT: Consultant or advisory role (Novartis). CFDL: Consultant or advisory role (Janssen, Celgene/Bristol-Myers, GSK), honoraria (Janssen, Celgene/Bristol-Myers, Amgen, GSK), research funding (Janssen, Celgene/Bristol-Myers, Amgen, Takeda). GC: Consultant or advisory role (Celgene, Novartis). JE: Consultant or advisory role (Abbvie, Novartis, Celgene, Astellas, Jazz, Daiichi Dankyo, Roche, Amgen, Pfizer), travel grants (Celgene, Roche, Astellas, Daiichi Dankyo), research funding (Novartis, Celgene). AU-I: Consultant or advisory role (Kite Gilead, Celgene/Bristol-Myers, Miltenyi), travel grants (Kite Gilead, Celgene/Bristol-Myers). MJ: Consultant or advisory role (Kite Gilead, Grifols), honoraria (Kite Gilead, Grifols).
- Subjects :
- Adolescent
Adult
Aged
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local immunology
Neoplasm Recurrence, Local pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
Prognosis
Survival Rate
Young Adult
Antigens, CD19 immunology
Cell- and Tissue-Based Therapy methods
Drug Resistance, Neoplasm
Neoplasm Recurrence, Local therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Receptors, Antigen, T-Cell immunology
Salvage Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2051-1426
- Volume :
- 9
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal for immunotherapy of cancer
- Publication Type :
- Report
- Accession number :
- 34907029
- Full Text :
- https://doi.org/10.1136/jitc-2021-003644